AXGN:NASDAQ
AxoGen, Inc Common Stock
55,93 $
arrow_upward
+0,96%(+0,53) 1D
13 қар., 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
55,88 $
High
57,46 $
Low
55,01 $
Mkt. cap
3,34 млрд
Avg. vol.
1,98 млн
Volume
1,38 млн
52-wk high
59,72 $
52-wk low
23,00 $
EPS
-0,68 $
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
Open
55,88 $
High
57,46 $
Low
55,01 $
Mkt. cap
3,34 млрд
Avg. vol.
1,98 млн
Volume
1,38 млн
52-wk high
59,72 $
52-wk low
23,00 $
EPS
-0,68 $
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
News stories
From web sources and news partners
investingLive
·
2 сағат бұрын
Morgan Stanley goes max overweight global stocks, sees 15% S&P 500 upside on AI capex
The Motley Fool
·
9 сағат бұрын
This Dividend King Yields 5 Times the S&P 500. Is It a Buy Now?
TradingKey
·
1 күн бұрын
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
BigGo Finance
·
15 сағат бұрын
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Флорида, Америка Құрама Штаттары
SectorHealth Care
IndustryMedical device
Websiteaxogeninc.com